Compare CF & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CF | UTHR |
|---|---|---|
| Founded | 1946 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.0B | 20.3B |
| IPO Year | 2005 | 1999 |
| Metric | CF | UTHR |
|---|---|---|
| Price | $78.05 | $488.92 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 15 | 12 |
| Target Price | $92.50 | ★ $495.08 |
| AVG Volume (30 Days) | ★ 2.4M | 424.3K |
| Earning Date | 11-05-2025 | 10-29-2025 |
| Dividend Yield | ★ 2.57% | N/A |
| EPS Growth | ★ 31.44 | 16.08 |
| EPS | 8.27 | ★ 26.38 |
| Revenue | ★ $6,736,000,000.00 | $3,128,400,000.00 |
| Revenue This Year | $21.13 | $13.64 |
| Revenue Next Year | N/A | $5.78 |
| P/E Ratio | ★ $9.42 | $18.55 |
| Revenue Growth | 12.59 | ★ 13.50 |
| 52 Week Low | $67.34 | $266.98 |
| 52 Week High | $104.45 | $492.62 |
| Indicator | CF | UTHR |
|---|---|---|
| Relative Strength Index (RSI) | 38.45 | 68.10 |
| Support Level | $78.08 | $470.13 |
| Resistance Level | $80.94 | $492.62 |
| Average True Range (ATR) | 1.96 | 10.72 |
| MACD | 0.12 | -0.53 |
| Stochastic Oscillator | 16.70 | 89.55 |
CF Industries is a leading producer and distributor of nitrogen, which is primarily used in fertilizers. The company operates nitrogen manufacturing plants primarily in North America. CF also produces nitrogen in the United Kingdom and holds a joint venture interest in a nitrogen production facility in Trinidad and Tobago. CF makes nitrogen primarily using low-cost US natural gas as its feedstock, making the company one of the lowest-cost nitrogen producers globally. It is also investing in carbon-free blue and green ammonia, which can be used as an alternative fuel to hydrogen or as a means to transport hydrogen.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.